{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:09Z","timestamp":1792528269338,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Over the last two decades, oral small molecules that target intracellular protein kinases that mediate intracellular signaling have been found to be effective in multiple immune mediated inflammatory diseases (IMIDs). Tofacitinib was the first Janus kinase inhibitor (JAKi) approved for rheumatoid arthritis (RA) in 2012 and subsequently baricitinib, upadacitinib, and filgotinib have been approved by various regulatory agencies around the world. Substantial efficacy in RA as well as other rheumatic diseases (axial spondyloarthritis, psoriatic arthritis, giant cell arteritis) and other IMIDs (inflammatory bowel disease, atopic dermatitis) has been demonstrated. Various JAKi are in trials for lupus, inflammatory myopathies and Sjogrens with recent positive results noted in phase 2\/3 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Although efficacy has been clearly demonstrated safety concerns have been raised based on the oral surveillance postmarketing clinical trial which demonstrated in RA patients \u2265\n                      <jats:underline>50<\/jats:underline>\n                      years old with cardiovascular risk factors treated with tofacitinib have an increase risk of venous thromboembolism and possibly major adverse cardiovascular events\/malignancy compared to tumor necrosis factor inhibitor treated patients. Extensive investigations in clinical trials and real world observations over the last few years have addressed the safety issues with mixed results but have allowed for risk stratification and appropriate use of JAKi. Efforts to develop JAKi that are more selective for specific JAK isoforms are ongoing such as deucravacitinib \u2013 a TYK2 inhibitor with a different mechanism of action compared to other JAKi that might have an enhanced safety profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Increased use of JAKi in the management of IMIDs is ongoing and will accelerate if the positive results noted in trials for lupus, inflammatory myopathies, and psoriatic arthritis result in regulatory approval. The article highlighted in this review provide an update on the progress being made in newer rheumatic disease indications as well as efforts to better understand the adverse event profile for patients on treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Delineation of the JAK\u2013STAT pathway critical for type 1\/II cytokine signaling in late 1990s resulted in the development of multiple JAKi for IMIDs. Tofacitinib was the original JAK inhibitor approved in 2012 followed by baricitinib in 2017 and upadacitinib in 2019 with filgotinib and pefecitinib approved ex-US all for rheumatoid arthritis. Since the original approval JAK inhibitors have been approved for multiple IMIDs. In this manuscript, data from clinical trials evaluating JAK inhibitors for new IMID indications will be reviewed as well as an update on safety data from real world experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001154","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:01:33Z","timestamp":1773752493000},"page":"176-181","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advances in the use of Janus kinase inhibitors"],"prefix":"10.1097","volume":"38","author":[{"given":"Stanley","family":"Cohen","sequence":"first","affiliation":[{"name":"UTSouthwestern Medical School, Rheumatology Division, THR Presbyterian Hospital, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[{"name":"School of Medicine, Divisions of Infectious Diseases and Ophthalmology, School of Public Health, Oregon Health and Sciences University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","journal-title":"NEJM"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheum"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"881","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann rheum Dis"},{"key":"R9-20260401","article-title":"Efficacy and safety of deucravacitinib up to week 52: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs","author":"Van der Heidje","year":"2025","journal-title":"ACR Convergence Meeting 2015 Abstract LB20"},{"key":"R10-20260401","article-title":"Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from a phase 2 program","author":"Morand","year":"2025","journal-title":"ACR Convergence Meeting; LB10 Abstract"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","journal-title":"JAMA Dermatol"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","article-title":"Highly selective tyrosine kinase 2 inhibtion with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomized phase 2b study","volume":"84","author":"Kivitz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"e0057423","DOI":"10.1136\/rmdopen-2025-005742","article-title":"Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104\u200aweeks in a long-term extension study","volume":"11","author":"Merrill","year":"2025","journal-title":"RMD Open"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"29","author":"Blockmanns","year":"2025","journal-title":"NEJM"},{"key":"R16-20260401","article-title":"Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the re-randomized, double-blind SELECT-GCA phase 3 trial","author":"Schmidt","year":"2025","journal-title":"ACR Convergence 2025:Abstract 0776"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"1382728","DOI":"10.3389\/fimmu.2024.1382728","article-title":"Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis\/dermatomyositis: a single-arm systemic meta-analysis","volume":"15","author":"Chenhang","year":"2024","journal-title":"Front Immune"},{"key":"R18-20260401","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"412","author":"Paik","year":"2023","journal-title":"Clin Exp Rheum"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"e004987","DOI":"10.1136\/rmdopen-2024-004987","article-title":"Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry","volume":"11","author":"Miyazaki","year":"2025","journal-title":"RMD Open"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question \u2013 data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharm"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-025-03565-0","article-title":"Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster","volume":"27","author":"Curtis","year":"2025","journal-title":"Arthritis Res"},{"key":"R25-20260401","first-page":"7005","article-title":"Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis","volume":"25","author":"Hu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41927-024-00376-9","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"8","author":"Fazal","year":"2024","journal-title":"BMC Rheum"},{"key":"R27-20260401","article-title":"Trends in incidence and predictors of incident venous thromboembolism in patients with rheumatoid arthritis: a population-based retrospective cohort study","author":"Frechette","year":"2025","journal-title":"EULAR2025 Abstract OP0070"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/OARRR.S284757","article-title":"Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors","volume":"14","author":"Omair","year":"2022","journal-title":"Open Access Rheum"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"NEJM"},{"key":"R30-20260401","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"735","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R31-20260401","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13075-025-03528-5","article-title":"Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study","volume":"27","author":"Oster","year":"2025","journal-title":"Arth Res Ther"},{"key":"R32-20260401","first-page":"1","article-title":"Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years","volume":"9","author":"Burmester","year":"2024","journal-title":"Ann rheum Dis"},{"key":"R33-20260401","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum dis"},{"key":"R34-20260401","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum dis"},{"key":"R35-20260401","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2024024187","article-title":"JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism","volume":"143","author":"Zon","year":"2024","journal-title":"Blood"},{"key":"R36-20260401","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ueg2.12584","article-title":"Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2\u200ayears of drug exposure","volume":"12","author":"Panes","year":"2024","journal-title":"United Eur Gastro"},{"key":"R37-20260401","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research Consortium Multicenter National Cohort Study","volume":"5","author":"Ma","year":"2023","journal-title":"Am Jl Gastro"},{"key":"R38-20260401","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/medicina61091692","article-title":"Upadacitinib in biologic-experienced inflammatory bowel disease: real-world efficacy, safety, and laboratory outcomes","volume":"61","author":"Osdogan","year":"2025","journal-title":"Medicina"},{"key":"R39-20260401","doi-asserted-by":"crossref","first-page":"e005033","DOI":"10.1136\/rmdopen-2024-005033","article-title":"Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes","volume":"11","author":"Mariette","year":"2025","journal-title":"RMD Open"},{"key":"R40-20260401","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/annrheumdis-2024-eular.793","article-title":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease venous thromboembolism and cancer in psoriatic arthritis and axial spondyloarthritis","volume":"83","author":"Zhao","year":"2024","journal-title":"Ann rheum Dis"},{"key":"R41-20260401","doi-asserted-by":"crossref","first-page":"1189389","DOI":"10.3389\/fphar.2023.1189389","article-title":"Risk of venous thromboembolism with Janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharm"},{"key":"R42-20260401","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R43-20260401","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R44-20260401","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R45-20260401","doi-asserted-by":"crossref","first-page":"e003630","DOI":"10.1136\/rmdopen-2023-003630","article-title":"Comparative cardiovascular safety with Janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"key":"R46-20260401","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.43188","article-title":"Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an International Collaboration of Registries","volume":"77","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R47-20260401","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:01:18Z","timestamp":1775030478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001154","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}